Exciting Leadership Transition at Neuronetics
Neuronetics, Inc., a forward-thinking medical technology firm, has announced a significant leadership change that aims to further enhance its mission to transform mental healthcare. The company has appointed Steven Pfanstiel as its new Chief Financial Officer, taking over from the esteemed Steve Furlong. This strategic move follows a planned succession process aimed at ensuring the continuity of Neuronetics' steadfast commitment to serving its patients effectively.
Welcome to Steven Pfanstiel, New CFO
Steven Pfanstiel joins Neuronetics with a wealth of experience, particularly in the healthcare sector. He has an impressive track record in finance, having previously served as CFO and COO at Marinus Pharmaceuticals. His leadership at Marinus was pivotal during the successful launch of their flagship product, Ztalmy. Steven’s extensive expertise in both medical technology and pharmaceuticals positions him perfectly to contribute to Neuronetics' ongoing growth and innovation.
Continuity and Transition for Neuronetics
Steve Furlong, who has been an exemplary leader for the last six years, will remain onboard as a Senior Advisor until March 2026. His experience and insights will be invaluable during this transition period, allowing for a smooth and effective handover of responsibilities. As Keith J. Sullivan, the President and CEO, highlighted, Furlong’s efforts in shaping the financial landscape of Neuronetics have been crucial in overcoming market challenges and executing vital acquisitions.
Strategic Vision Moving Forward
With Steven Pfanstiel's leadership, Neuronetics aims to enhance its strategic vision and expand its access to mental health therapies, which have already made a notable impact on patient care. The incorporation of advanced neurohealth treatments sets the stage for promising growth as Neuronetics leverages its innovative NeuroStar TMS technology.
Focus on Mental Health Innovations
The NeuroStar Advanced Therapy System stands as a testament to the company’s commitment to mental health. This non-invasive treatment option has already improved the quality of life for many individuals with Major Depressive Disorder (MDD) and other conditions. With over 7.4 million treatments administered and the support of extensive clinical data, Neuronetics is solidly positioned to pioneer advancements in mental health treatment solutions.
Future Outlook for Neuronetics
Neuronetics is optimistic about the future and has reaffirmed its guidance for 2025. Despite challenges, the company is on track to achieve positive cash flow, marking a significant operational milestone that reflects its commitment to sustainable growth. Moving forward, Neuronetics’ focus will be on harnessing the strengths of both the NeuroStar TMS technology and its expanding network of clinics, ensuring broader access to crucial mental health services.
About Neuronetics, Inc.
Neuronetics, Inc. is dedicated to the belief that mental health is fundamental to overall health. Armed with innovative treatment options like the NeuroStar Advanced Therapy System, the company is at the forefront of enhancing patient care in mental health. Neuronetics also operates Greenbrook TMS Inc., providing critical treatments for MDD and other mental health disorders across numerous locations.
Frequently Asked Questions
Who is the new CFO of Neuronetics?
Steven Pfanstiel has been appointed as the new Chief Financial Officer.
What experience does Steven Pfanstiel bring to Neuronetics?
Steven has extensive experience in the healthcare sector, previously serving as CFO at Marinus Pharmaceuticals where he led significant initiatives.
What will happen to Steve Furlong after the transition?
Steve Furlong will act as a Senior Advisor until March 2026 to ensure a smooth transition.
What is the focus of Neuronetics going forward?
Neuronetics aims to expand access to its advanced mental health treatments while maintaining a focus on sustainable growth.
What is the significance of the NeuroStar Advanced Therapy System?
This system represents a leading-edge treatment for those suffering from major depressive disorder, emphasizing Neuronetics' commitment to innovative healthcare solutions.
